Webinar: Optimizing Your Blood Center’s Pathogen Reduced Platelet Inventory
The deadline for implementation of the FDA bacterial guidance, March 31, 2021, is quickly approaching. The guidance outlines strategies to reduce the risk of bacterial transfusion transmission (TTI) in platelet components, including pathogen reduction (PR) and various testing approaches. This webinar highlights two case studies that demonstrate how blood centers can achieve a >70% pathogen reduced platelet component inventory to meet hospital demand, while complying with FDA Guidance requirements.
Case studies presented will:
- Show the development of a PR scale-up plan correlated to hospital demand and roll-out
- Describe measures implemented to achieve an inventory of ~100% pathogen reduced platelets
- Illustrate how PR increased platelet availability through decreased expiry rates with the elimination of culture holds
Beau Robertson - Cerus Corporation
Nichole Miller - Versiti Blood Center of Michigan
Tracy Collier - Community Blood Bank of NWPA and WNY
Watch the replay
Click here or the image below. Runtime: ~45 minutes.
Beau Robertson | Director, Blood Center Services Deployment, Cerus Corporation
Nichole Miller MSTM (SBB) ASCP | Director, Specialized Production, Versiti Blood Center of Michigan
Nichole has worked for Versiti Wisconsin for 12 years were she held several roles in the blood field, including: research, donor management and blood operations. She currently manages the blood quality control testing and platelet production laboratories and has focused on implementing pathogen reduced platelets in Wisconsin, Illinois, Michigan and Indiana. Nichole completed her Specialist in Blood Banking certification in 2014 and attained her Masters in Transfusion Medicine in 2018 at Marquette University. When not working, Nichole volunteers for the Wisconsin Association of Blood Banks as the president for the 2019–2020 term.
Tracy Collier | Technical Director, Community Blood Bank of NWPA and WNY